At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 121 enrolled
Drug / intervention
BMN 111 +1 moredrug
Likely dose
BMN 111 15 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
In Brief
A Phase 3 clinical trial evaluating BMN 111 and Placebo for Achondroplasia. Completed, enrolled 121 participants across 24 sites in 7 countries.
Detailed Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAchondroplasia
CountriesAustralia, Germany, Japan, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJun 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartDec 12, 2016
Primary CompletionOct 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.0 years ago
Interventions
BMN 111drug
Subcutaneous injection of 15 μg/kg of BMN 111 daily
Placebodrug
Subcutaneous injection of 15 μg/kg of placebo daily